Paper42582425
Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.
Ramadurgum P and 3 others. Front Pharmacol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist. Papers, record 42582425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42582425
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Potential nephroprotective mechanisms of orforglipron, an oral non-peptide GLP-1 receptor agonist.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12190331 | Mechanisms of clinically relevant drug interactions associated with tacrolimus. | Clin Pharmacokinet | 2002 | https://conductscience.org/library/papers/12190331 | PubMed |
| 2 | 40129942 | Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40129942 | PubMed |
| 3 | 41506360 | Acute kidney injury: Detection, risk stratification, and predictive biomarkers. | Clin Chim Acta | 2026 | https://conductscience.org/library/papers/41506360 | PubMed |
| 4 | 41683830 | Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41683830 | PubMed |
| 5 | 38742021 | Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity. | Front Nutr | 2024 | https://conductscience.org/library/papers/38742021 | PubMed |
| 6 | 39728000 | Spotlight on the Mechanism of Action of Semaglutide. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39728000 | PubMed |
| 7 | 22205779 | Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro. | Drug Metab Dispos | 2012 | https://conductscience.org/library/papers/22205779 | PubMed |
| 8 | 40544435 | Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40544435 | PubMed |
| 9 | 38796653 | Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. | Nat Med | 2024 | https://conductscience.org/library/papers/38796653 | PubMed |
| 11 | 39364792 | Glucagon-like peptide-1 receptor agonists and kidney outcomes. | J Diabetes | 2024 | https://conductscience.org/library/papers/39364792 | PubMed |
| 12 | 41880122 | GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes. | Curr Cardiol Rep | 2026 | https://conductscience.org/library/papers/41880122 | PubMed |
| 13 | 38414573 | Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. | Obes Sci Pract | 2024 | https://conductscience.org/library/papers/38414573 | PubMed |
| 14 | 38785209 | Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38785209 | PubMed |
| 15 | 37344954 | Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. | Diabetes Obes Metab | 2023 | https://conductscience.org/library/papers/37344954 | PubMed |
| 16 | 33449915 | Decreased expression of the GLP-1 receptor after segmental artery injury in mice. | J Endocrinol | 2021 | https://conductscience.org/library/papers/33449915 | PubMed |
| 17 | 33177239 | Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/33177239 | PubMed |
| 18 | 18388866 | Emerging evidence of the impact of kidney disease on drug metabolism and transport. | Clin Pharmacol Ther | 2008 | https://conductscience.org/library/papers/18388866 | PubMed |
| 19 | 40920377 | GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes. | JAMA Netw Open | 2025 | https://conductscience.org/library/papers/40920377 | PubMed |
| 20 | 28538729 | Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. | Nature | 2017 | https://conductscience.org/library/papers/28538729 | PubMed |
| 21 | 39856432 | Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control. | Acta Pharmacol Sin | 2025 | https://conductscience.org/library/papers/39856432 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ARRB1 | 408 | PubTator's text mining | https://conductscience.org/library/genes/408 | NCBI Gene |
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42582425
GET https://conductscience.org/api/papers/v1/42582425/references?page=2